Nyxoah’s VAC Approval Bottleneck Could Test Whether Genio’s Momentum Is Scalable

The market's reaction to Nyxoah's fourth-quarter results was a textbook case of optimism in motion. On the day of the earnings call, the stock surged over 12%. This pop was directly fueled by the headline number: 347% year-over-year revenue growth for the quarter. For context, this was the company's first full quarter of commercial sales in the United States following its FDA approval in August 2025. The consensus view, reflected in the price action, is clear: the Genio launch is a success story in the making.

The narrative is one of a powerful new product finding its footing. Management highlighted positive surgeon and patient feedback, consistent reimbursement from both commercial payors and Medicare, and a solid foundation of trained surgeons and activated accounts. All of this points to a company that has crossed a critical threshold from development to commercial execution. The market is pricing in that momentum, betting that the explosive growth seen in Q4 is just the beginning of a multi-year expansion.

Yet, this is where the "priced for perfection" narrative takes hold. The stock's sharp move on strong numbers suggests the initial success is already reflected in the share price. The key question for investors now is whether the expectations gap has closed-or if it has only begun to widen. The current setup implies that any stumble in the path to sustained profitability, or any delay in scaling beyond the initial launch centers, could quickly deflate the recent optimism. The market has rewarded the launch; it now demands proof of a durable, scalable business model.

The Execution Gap: Early Metrics and Asymmetric Risks

The initial commercial success is real, but it is built on a foundation that is still remarkably small. In its first full quarter of U.S. sales, Nyxoah generated $4.5 million in revenue. While the 64% gross margin is healthy and suggests good unit economics, scaling from that base to meaningful profitability requires a massive expansion in volume. The company's current reach is a key constraint. With only 25 sales reps covering 125 of the 400 top accounts, the commercial rollout is in its infancy. This creates a significant gap between the company's potential addressable market and its actual sales force capacity. This early-stage setup introduces an asymmetric risk: the initial success could be a launch effect, not a scalable model. The company has made progress on reimbursement, with consistent coverage from both commercial payors and Medicare, and has trained 145 surgeons. Yet, the bottleneck for new account activation is the value analysis committee (VAC) approval process. By year-end, the company had submitted 120 VAC applications, with only 57 approved. This approval rate of less than 50% is a critical early hurdle. It indicates that securing a place on hospital formularies is not guaranteed, and the pace of new account activations will be dictated by this slow-moving internal process, not just by sales force outreach.

The risk here is one of execution velocity. The market has priced in the launch momentum, but the path to sustained growth depends on the company's ability to rapidly scale its sales force and, more importantly, to convert its pipeline of VAC submissions into activated accounts. The current trajectory suggests a slow, sequential ramp. The company's own guidance for the first half of 2026-projecting a 25% sequential increase in U.S. net revenue-aligns with this cautious, incremental approach. For investors, the question is whether this measured pace is sufficient to justify the stock's recent pop, or if it sets up a classic expectations gap where the reality of scaling proves slower than the hype.

Financial Runway and Competitive Landscape

Nyxoah's financial position provides a solid runway to navigate the scaling phase, but the path to profitability will require disciplined investment. The company ended 2025 with €48.0 million in cash, a figure that supports its ambitious 2026 plan to expand its U.S. sales force to 40 reps and activate 200 accounts. This capital buffer is crucial, as scaling from a base of just 57 activated accounts and 145 trained surgeons will demand significant spending on personnel, marketing, and the ongoing VAC approval process. The company's 64% gross margin offers a healthy foundation, but it must cover these ramp-up costs while also funding global manufacturing expansion and clinical studies. The market has priced in the launch momentum, but the financial reality is one of investing heavily in growth now to capture market share later.

The competitive landscape, however, presents a more nuanced challenge. While the total addressable market for OSA is vast-estimated at 936 million people globally-Genio targets a specific, niche segment: patients with moderate to severe OSA who cannot tolerate CPAP therapy. This focus is a double-edged sword. It allows Nyxoah to avoid direct competition with the dominant CPAP market, but it also caps the immediate growth ceiling for the product. The company must demonstrate long-term efficacy and safety to maintain its position within this niche and secure favorable reimbursement, which is currently consistent but not guaranteed.

Furthermore, the company faces competition from established players in the surgical neurostimulation space. While Genio's battery-free, leadless design is a key differentiator, entrenched competitors may respond with their own innovations or pricing strategies. The real competitive pressure, though, may come from within the category itself. As the market for alternative OSA therapies grows, the risk is not of a single rival overtaking Nyxoah, but of the category becoming more crowded, potentially compressing margins and increasing the cost of patient acquisition over time. For now, the company's niche focus and strong early reimbursement provide a defensible position, but the financial runway must be managed carefully to ensure it lasts long enough to prove the model's scalability.

Catalysts and Watchpoints: Testing the Thesis

The investment thesis now hinges on a series of near-term milestones that will test whether the initial launch momentum is sustainable or a fleeting event. The primary catalyst is the execution of the company's 2026 plan to expand its U.S. footprint to 40 sales reps and 200 accounts. This expansion is the tangible proof point for scalability. Investors should monitor two key metrics to gauge market acceptance: the rate of new surgeon training and, more critically, the value analysis committee (VAC) approval rate. The company had 120 VAC submissions with 57 approvals by year-end, a rate below 50%. A significant acceleration in approvals will signal that hospitals are embracing Genio, while stagnation would confirm the approval process as a major bottleneck.

The most direct test of the expectations gap will be the trajectory of quarterly revenue growth. The market has priced in the explosive 347% year-over-year surge from the first full quarter of sales. The company's own guidance for a 25% sequential increase in U.S. net revenue in the first half of 2026 sets a clear, but moderate, benchmark. Any material deceleration from that path would be a red flag, suggesting the launch effect was a one-time event and that scaling beyond the initial 125 accounts is proving harder than anticipated. Conversely, exceeding the sequential growth target would validate the commercial rollout plan and support the stock's recent pop.

Other watchpoints include the company's cash burn and the clinical timeline. The CFO stated a near-term burn rate of approximately €20 million per quarter, with capital raises extending the runway into 2027. This provides time, but the company must demonstrate that its investment is converting into revenue at a faster pace than the burn rate. On the clinical front, the ACCESS study 12-month data due by July 2026 and the planned PMA supplement submission for label expansion are critical for long-term differentiation and market access. However, for the near-term thesis, the focus remains squarely on the sales force expansion and the VAC approval rate. These are the metrics that will determine if the company can translate its promising start into a durable, scalable business.